CN117979992A - 钩端螺旋体毒力调节蛋白及其用途 - Google Patents

钩端螺旋体毒力调节蛋白及其用途 Download PDF

Info

Publication number
CN117979992A
CN117979992A CN202280062844.1A CN202280062844A CN117979992A CN 117979992 A CN117979992 A CN 117979992A CN 202280062844 A CN202280062844 A CN 202280062844A CN 117979992 A CN117979992 A CN 117979992A
Authority
CN
China
Prior art keywords
seq
lic
lmanv2
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280062844.1A
Other languages
English (en)
Chinese (zh)
Inventor
约瑟夫·维内兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of CN117979992A publication Critical patent/CN117979992A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280062844.1A 2021-08-06 2022-08-05 钩端螺旋体毒力调节蛋白及其用途 Pending CN117979992A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163230244P 2021-08-06 2021-08-06
US63/230,244 2021-08-06
PCT/US2022/074601 WO2023015290A1 (en) 2021-08-06 2022-08-05 Leptospiral virulence modulating proteins and uses thereof

Publications (1)

Publication Number Publication Date
CN117979992A true CN117979992A (zh) 2024-05-03

Family

ID=85156339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280062844.1A Pending CN117979992A (zh) 2021-08-06 2022-08-05 钩端螺旋体毒力调节蛋白及其用途

Country Status (6)

Country Link
US (1) US20240277823A1 (enExample)
EP (1) EP4380608A4 (enExample)
JP (1) JP2024529044A (enExample)
CN (1) CN117979992A (enExample)
AU (1) AU2022323324A1 (enExample)
WO (1) WO2023015290A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025208019A1 (en) * 2024-03-29 2025-10-02 Yale University Leptospiral virulence modulating protein epitopes and uses thereof
WO2026006400A2 (en) * 2024-06-25 2026-01-02 Luna Bioscience, Inc. A virulence modifying protein-based recombinant vaccine and rapid diagnostic assay for leptospira

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700263A1 (ru) * 2004-07-01 2007-06-29 Кебенхавнс Университет Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции
AU2016219787B2 (en) * 2015-02-20 2019-05-30 Calixar Leptospira immunoprotective proteins and methods of identification and use thereof
EP4100050A4 (en) * 2020-02-07 2024-07-10 Yale University Leptospiral proteins and uses thereof

Also Published As

Publication number Publication date
WO2023015290A1 (en) 2023-02-09
AU2022323324A1 (en) 2024-03-21
EP4380608A4 (en) 2026-04-15
EP4380608A1 (en) 2024-06-12
US20240277823A1 (en) 2024-08-22
JP2024529044A (ja) 2024-08-01

Similar Documents

Publication Publication Date Title
JP7506930B2 (ja) クラミジア種（Ｃｈｌａｍｙｄｉａ ｓｐ．）に対するワクチン
KR20120093141A (ko) 폐렴구균(Ｓｔｒｅｐｔｏｃｏｃｃｕｓ Ｐｎｅｕｍｏｎｉａｅ)에 대항하는 백신과 조성물
US20150197558A1 (en) Binding moieties for biofilm remediation
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
JP6894237B2 (ja) 変異体ブドウ球菌抗原
KR20220128372A (ko) Fimh 돌연변이체, 이를 갖는 조성물 및 이의 용도
JP2015500827A (ja) Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ毒素ベースのワクチン
JP2015529677A (ja) ワクチンとしてのＣｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅポリペプチド
BR112020016373A2 (pt) Composição imunogênica compreendendo antígenos de estafilococos
CN114423448A (zh) 疫苗组合物和选择抗原的方法
EA025831B1 (ru) Композиции из hyr1-производных и способы лечения ими
US20240277823A1 (en) Leptospiral virulence modulating proteins and uses thereof
US12595287B2 (en) Leptospiral proteins and uses thereof
JP2019504636A (ja) Ｓｌａｍポリヌクレオチド及びポリペプチド、ならびにそれらの使用
EP4598943A2 (en) Novel chimeric multi-protein based recombinant vaccine antigens for prevention of lyme disease in animals and humans
JP2019531100A (ja) ワクチン構築物およびブドウ球菌感染症に対するその使用
US10646561B2 (en) Compositions and methods for using Salmonella typhi toxin to induce or enhance an immune response
HK40106181A (en) Leptospiral virulence modulating proteins and uses thereof
JP2021524485A (ja) パラ結核症のための免疫原性組成物
US10335477B2 (en) Compositions and methods for diagnosing, preventing and treating Salmonella typhi and Salmonella paratyphi infection
JP2021505525A (ja) Ａ群レンサ球菌に対する免疫原性ペプチド
Fegan et al. Rational selection of TbpB variants elucidates a bivalent vaccine formulation with broad spectrum coverage against Neisseria gonorrhoeae
WO2025208019A1 (en) Leptospiral virulence modulating protein epitopes and uses thereof
Chanda et al. Bridging Gaps in Antibody Responses and Animal Welfare: Assessing Blood Collection Methods and Vaginal Immunity in Mice Immunized with Intranasal Gonococcal Vaccines
EP3450556B1 (en) Peptide inhibiting colonization by pathogenic bacteria, and colonization inhibitor including same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106181

Country of ref document: HK